Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study on the Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) Injection in Patients With Critical Limb Ischemia

NCT06359912 is registered in ClinicalTrials.gov with Allife Medical Science and Technology Co., Ltd. as lead sponsor.

NCT NCT06359912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06359912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study on the Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) Injection in Patients With Critical Limb Ischemia
Lead sponsor
Allife Medical Science and Technology Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2024
Completion date
July 31, 2025
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia